Nabriva Therapeutics plc Securities Litigation

If you purchased a significant amount of shares of Nabriva Therapeutics plc (NASDAQ: NBRV), you have certain options. Investors should register for updates.

 

Lawsuit Overview

Defendant:Nabriva Therapeutics plc
Date Filed:May 8th, 2019
Sector:Health Care
Industry:Major Pharmaceuticals

According to the Complaint, Nabriva Therapeutics plc is a biopharmaceutical company that purports to develop novel antiinfective agents to treat serious infections. One of the Company's product candidates is CONTEPO, an epoxide antibiotic developed by Zavante Therapeutics ("Zavante"), which the Company acquired in July 2018.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, the Complaint alleges Defendants failed to disclose to investors: (1) that the Company's manufacturers failed to meet good manufacturing practices; (2) that these manufacturers would be subject to inspections by the FDA in connection with the Company's NDA; (3) that, as a result of the manufacturing deficiencies, the Company's NDA for CONTEPO was unlikely to be approved by the FDA; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Nabriva Therapeutics plc

 
First Identified Complaint

Larry Enriquez, et al. v. Nabriva Therapeutics plc, et al.

Date Filed:May 8th, 2019
Class Period Start:November 1st, 2018
Class Period End:April 30th, 2019
First Identified Complaint Filings
#Document TitleFiling Date